Skip to main content

NEURONAL SELF-RENEWAL BY ANTIGEN-SPECIFIC TOLERIZATION IN MULTIPLE SCLEROSIS REINSTALLING THE BALANCE BETWEEN INFLAMMATION AND REGENERATION

Objective

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which no cure is currently available. It is the leading cause of non-traumatic disabling neurological disease in young adults with more than 500,000 people affected in Europe. As chronic inflammatory processes drive the neurodegeneration, we hypothesize that improved clinical outcome can be achieved by restoring the balance between inflammation and the remaining capacity of neuronal self-renewal. In this context, cell therapy that specifically targets the damaging immune reactions that cause MS, thereby reducing the autoreactive, inflammatory assaults in MS without affecting protective immunity against pathogens and cancer, can be a promising approach to allow for more repair. Recently, we set-up a collaborative network of European centers working in cell therapy (COST Action BM1305). From this, a multidisciplinary team from four different EU countries (B, ES, NL and GER) with two additional partners now aims to safely reach the next level of testing and joins efforts to bring antigen-specific cell therapy for MS to the clinic. Our objectives are to evaluate safety, clinical practicality and demonstrate first proof-of-principle of therapeutic efficacy of antigen-specific tolerance-inducing dendritic cells (tolDC) in MS patients in two single-center clinical trials. All regulatory approvals are already in place. Coordinated patient monitoring and centralized MRI monitoring, including radiological correlates of neurodegeneration, and immunomonitoring will enable us to directly compare results between trials and enable consented biobanking, data safeguarding and accessibility to support future efforts in the field of MS therapy. ReSToRe focuses on the advancement of an innovative cell therapy approach with the potential to improve the lives of patients suffering from MS, a currently untreatable disease. This would represent a breakthrough for healthcare in MS.

Call for proposal

H2020-SC1-2017-Single-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSITEIT ANTWERPEN
Address
Prinsstraat 13
2000 Antwerpen
Belgium
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 911 176,25

Participants (7)

UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Belgium
EU contribution
€ 660 056,25
Address
Drie Eikenstraat 655
2650 Edegem
Activity type
Research Organisations
UNIVERSIDAD DE NAVARRA
Spain
EU contribution
€ 625 000
Address
Campus Universitario Edificio Central
31080 Pamplona
Activity type
Higher or Secondary Education Establishments
INSTITUT CATALA DE LA SALUT
Spain
EU contribution
€ 1 170 212,50
Address
Gran Via De Les Corts Catalanes 587
08007 Barcelona
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Stichting Sanquin Bloedvoorziening
Netherlands
EU contribution
€ 911 250
Address
Plesmanlaan 125
1006 AN Amsterdam
Activity type
Research Organisations
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
Germany
EU contribution
€ 363 837,50
Address
Schlossplatz 2
48149 Muenster
Activity type
Higher or Secondary Education Establishments
ICOMETRIX NV
Belgium
EU contribution
€ 530 500
Address
Kolonel Begaultlaan 1B
3012 Leuven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STICHTING LYGATURE
Netherlands
EU contribution
€ 185 000
Address
Jaarbeursplein 6
3521 AL Utrecht
Activity type
Other